Curriculum

CURRICULUM VITAE

2. Current position
Professor of neurology, University of Southern Denmark
Consultant, Department of Neurology, Odense University Hospital 

3. Other positions
2000- Member of national board for drug registration, Danish Medicines Agency 

4. Education and authorisations
1984 Medical degree, Odense University.
1984 Authorisation as a Physician, National Board of Health, Copenhagen
1985 Permission to Practice Independently as a Physician, National Board of Health, Copenhagen
1993 Dr. Med. Sci., Odense University
1997 Authorisation as a Specialist in Neurology, National Board of Health, Copenhagen 

5. Research and teaching positions
1988-1991 Research fellow, Department of Clinical Pharmacology, Odense University
1996-1998, 1999 Associate professor of pharmacotherapy, Department of Clinical Pharmacology, Odense University
1996 Associate professor of neurology, Århus University
1998-1999, 1999-2001 Associate professor of neurology, University of Southern Denmark
2003- Professor of neurology, University of Southern Denmark 

6. Research guidance
Supervisor or co-supervisor of 8 completed and 4 current PhD studies
Supervisor of 1 and co-supervisor of 2 pre-graduate diploma studies 

7. Research communication
More than 25 invited lectures at international scientific meetings 

8. Publications
About 100 original papers in journals with peer review, 15 review papers, and 15 book chapters published 

9. Reviewer of research communications
Reviewer of papers for Neurology, European Journal of Pain, Journal of Clinical Psychopharmacology, Analgesia and Pain. Associate editor, Pain (Clinical Section) 

10. GCP Experience
Participation as principal investigator and co-investigator in several GCP-monitored trials.1989-1993 10 2-3 days courses in clinical pharmacology including in January 1992 ”course in development and testing of drugs” including training in GCP.

22.04.2014 (SS)

UNDERVISNINGSPORTFOLIO

1. Formel pædagogisk uddannelse
Ingen 

2. Uddannelsesadministrative opgaver
Vice modultovholder ved modul på kandidatuddannelsen i medicin (K11) på Syddansk Universitet 2003-2013 og tovholder for samme fra 2013.
Overordnet ansvarlig for undervisning i neurologi ved kandidatuddannelsen i medicin på Syddansk Universitet fra 2003 (Modul K11, Modul K14, praktikanttjeneste ved neurologisk afdeling, færdighedstrænig i neurologi).
Uddannelseskoordinator (yngre læge) 1996 ved Neurologisk Afdeling, Aarhus Kommunehospital. 

3. Erfaring med undervisning, vejledning og eksamen
Undervisning i neurologi ved kandidatuddannelsen i medicin kontinuerligt fra 1993 ved ansættelser som klinisk lærer, klinisk lektor og professor ved Syddansk Universitet og Aarhus Universitet.
Undervisning i farmakologi ved kandidatuddannelsen i medicin 1988-1991 ved ansættelser som kandidatstipendiat og adjunkt ved Syddansk Universitet.
Undervisning i klinisk farmakologi som led i speciallægeuddannelse 1996-1998 ved ansættelse som klinisk lektor i farmakoterapi ved Syddansk Universitet.
Undervisning i klinisk farmakologi og neurologi ved en række hoveduddannelseskurser og phd-kurser 1991-2003.
Vejleder og medvejleder for en række speciale-, forskningsårs- og phd-studerende ved Syddansk Universitet kontinuerligt fra 1993.
I forbindelse med undervisning på bl.a. kandidatuddannelsen i medicin ved Syddansk Universitet erfaring med en række forskellige eksamensformer (mundtlig patientorienteret, OSCE (inklusiv med praktiske færdigheder), skriftlig (MCQ, MEC og essay)). 

4. Metoder, materialer og redskaber
Undervisning i form af forelæsninger, holdtimer og færdighedstræning
Udarbejdede noter og power pointpræsentationer 

5. Uddannelsesudvikling og universitetspædagogik
Ingen 

6. Refleksion over egen pædagogisk praksis og undervisningsevaluering
I alle undervisningsformer gøres i forskelligt omfang brug af student-involverende metode.
Evaluering af undervisning har typisk varieret fra over middel til god.

07.11.2014 (SS)

PUBLIKATIONER

Originalartikler
1. Kristensen O, Klitgård NA, Jønsson B, Sindrup SH. Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations. Acta Neurol Scand 1983; 68: 145-150.
2. Sindrup SH, Ejlertsen B, Gjessing H, Frøland A, Sindrup EH. Peripheral nerve function during hyperglycemic clamping in healthy subjects. Acta Neurol Scand 1988; 78: 141-145.
3. Wengler K, Matzen LE, Sindrup SH, Frøland A. Selvmonitorering af blodglukose og sygdomsforståelse hos patienter med insulinbehandlet diabetes. Sammenhæng med metabolisk regulation. Ugeskr Læger 1989; 151: 93-96.
4. Sindrup SH, Matzen LE, Wengler K, Frøland A, Reinholdt B. Klinisk kemiske parametre for metabolisk kontrol hos diabetespatienter. Nord Med 1989; 104: 50-51.
5. Sindrup SH, Ejlertsen B, Gjessing H, Svendsen A, Frøland A. Peripheral nerve function during hyperglycemic clamping in insulin dependent diabetic patients. Acta Neurol Scand 1989; 79: 412-418.
6. Sindrup SH, Ejlertsen B, Frøland A, Sindrup EH, Brøsen K, Gram LF. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in measures of peripheral and autonomic nerve function. Eur J Clin Pharmacol 1989; 37: 151-153.
7. Sindrup SH, Gram LF, Skjold T, Frøland A, Beck-Nielsen H. Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms. Clin Pharmacol Ther 1990; 47: 509-515.
8. Sindrup SH, Gram LF, Brøsen K, Eshøj O, Mogensen E. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990; 42: 135-144.
9. Matzen LE, Andersen BB, Jensen BG, Gjessing HJ, Sindrup SH, Kvetny J. Dif¬ferent effect of protein and carbohydrate on TSH, thyroid hormones, growth-hormo¬nes (GH), insulin, C-peptide, and glucagon in humans. Scand J Clin Lab Invest 1990; 50: 801-805.
10. Sindrup SH, Brøsen K, Gram LF. The nonlinear kinetics of imipramine in low and medium plasma level ranges. Ther Drug Monitor 1990; 12: 445-449.
11. Sindrup SH, Gram LF, Skjold T, Grodum E, Brøsen K, Beck-Nielsen H. Clomipra¬mine versus desipramine versus placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. Br J Clin Pharmacol 1990; 30: 683-691.
12. Sindrup SH, Brøsen K, Bjerring P, Arendt-Nielsen L, Larsen U, Angelo HR, Gram LF. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther 1990; 48: 686-693.
13. Sindrup SH, Grodum E, Gram LF, Beck-Nielsen H. Concentration-response relationship in paroxetine treatment of diabetic neuropathy. A patient-blinded dose escalation study. Ther Drug Monitor 1991; 13: 408-414.
14. Sindrup SH, Brøsen K, Gram LF, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TCG, Zussman BD. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 278-287.
15. Sindrup SH, Brøsen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine. Non-linearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 288-295.
16. Sindrup SH, Arendt-Nielsen L, Brøsen K, Bjerring P, Angelo HR, Eriksen B, Gram LF. The effect of quinidine on the analgesic effect of codeine. Eur J Clin Pharmacol 1992; 42: 587-592.
17. Sindrup SH, Tuxen C, Gram LF, Grodum E, Skjold T, Beck-Nielsen H. Lack of effect of mianserin on the symptoms of diabetic neuropathy. Eur J Clin Pharmacol 1992; 43: 251-255.
18. Sindrup SH, Bach FW, Gram LF. Plasma -endorphin is not affected by treatment with imipramine or paroxetine in patients with diabetic neuropathy symptoms. Clin J Pain 1992; 8: 145-148.
19. Sindrup SH, Bjerre U, Dejgaard A, Brøsen K, Aaes-Jørgensen T, Gram LF. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992; 52: 547-552.
20. Sindrup SH, Brøsen K, Hansen MGJ, Aaes-Jørgensen T, Overø KF, Gram LF. The pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monitor 1993; 15: 11-17.
21. Gram LF, Hansen MGJ, Sindrup SH, Brøsen K, Poulsen JH, Aaes-Jørgensen T, Overø KF. Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monitor 1993; 15: 18-24.
22. Brøsen K, Hansen MGJ, Nielsen KK, Sindrup SH, Gram LF. Paroxetine is a potent inhibitor of desipramine metabolism in extensive, but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993; 44: 349-355.
23. Sindrup SH, Poulsen L, Brøsen K, Arendt-Nielsen L, Gram LF. Are poor metaboli¬sers of sparteine less pain tolerant than extensive metabolisers ? Pain 1993; 53: 335-349.
24. Sindrup SH. Antidepressants in the treatment of diabetic neuropathy symptoms. Pharmacodynamic, -kinetic, and -genetic aspects (Thesis). Dan Med Bull 1994; 41: 66-78.
25. Thye-Rønn P, Sindrup SH, Arendt-Nielsen L, Brennum J, Nielsen OH, Beck-Nielsen H. The effect of short term hyperglycemia per se on nociceptive and non-nociceptive sensory thresholds. Pain 1994; 56: 43-49.
26. Arendt-Nielsen L, Brennum J, Sindrup SH, Bak P. Electrophysiological and psychophysical quantification of central temporal summation of the human nocicepti¬ve system. Eur J Appl Physiol 1994; 68: 266-273.
27. Hansen LM, Christensen PB, Sindrup SH, Olsen NK, Kristensen O, Laue Friis M. Interobserver variation in clinical neurological examination: patient-related factors. J Neurol 1994; 241: 492-496.
28. Hansen LM, Sindrup SH, Christensen PB, Olsen NK, Kristensen O, Laue Friis M. Interobserver variation in clinical neurological examination: observer dependent factors. Acta Neurol Scand 1994; 90: 145-149.
29. Poulsen L, Arendt-Nielsen L, Brøsen K, Gram LF, Nielsen KK, Sindrup SH. The analgesic effect of imipramine in different human experimental pain models. Pain 1995; 60: 287-293.
30. Hansen LM, Sindrup SH, Christensen PB, Olsen NK, Kristensen O, Laue Friis M. Interobservatørvariation i vurdering af neurologiske fund: undersøger- og patientaf¬hængige variable. Ugeskr Læger 1995; 157: 5394-5397.
31. Sindrup SH, Brøsen K. The pharmacogenetics of codeine hypoalgesia (Invited Review). Pharmacoge¬netics 1995; 5: 335-346.
32. Sindrup SH, Hofmann U, Asmussen J, Mikus G, Brøsen K, Nielsen F, Ingwersen SH, Christensen CB. Impact of quinidine on plasma and spinal fluid concentrations of codeine and morphine after codeine intake. Eur J Clin Pharmacol 1996; 49: 503-509.
33. Gaist D, Hallas J, Sindrup SH, Gram LF. Is overuse of sumatriptan a problem ? A population-based study. Eur J Clin Pharmacol 1996; 50: 161-165.
34. Poulsen L, Brøsen K, Arendt-Nielsen L, Gram LF, Elbæk K, Sindrup SH. Codeine and morphine in extensive and poor metabolisers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996; 51: 289-295.
35. Poulsen L, Arendt-Nielsen L, Brøsen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996; 60: 636-644.
36. Poulsen L, Arendt-Nielsen L, Brøsen K, Gram LF, Sindrup SH. Different effect of naloxone in extensive and poor metabolizers of sparteine ? Analgesia 1997; 2: 255-258.
37. David Gaist, Tsiropoulos I, Sindrup SH, Hallas J, Rasmussen BK, Kragstrup J, Gram LF. Heavy use of sumatriptan reflects inappropriate use: a population-based interview study. Br Med J 1998; 316: 1352-1353.
38. Poulsen L, Riishede L, Brøsen K, Clemmensen S, Sindrup SH. Codeine in post-operative pain. Study of the influence of sparteine phenotype and serum concentrations of morphine and morphine-6-glucuronide. Eur J Clin Pharmacol 1998; 54: 451-454.
39. Sindrup SH, Nielsen JC, Bjerring P, Arendt-Nielsen L. Imipramine does not affect argon laser induced pin prick pain thresholds and laser evoked cerebral potentials. Eur J Pain 1998; 2: 127-132.
40. Jeppesen U, Gaist D, Smith T, Sindrup SH. Statins and peripheral neuropathy. Eur J Clin Pharmacol 1999; 54: 835-838.
41. Sindrup SH, Andersen G, Madsen C, Smith T, Brøsen K, Jensen TS. Tramadol relieves pain and allodynia in polyneuropathy. A randomised, double-blind, controlled trial. Pain 1999; 83: 85-90.
42. Danish University Antidepressant Group. Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Clin Pharmacol Ther 1999; 66: 152-165.
43. Sindrup SH, Madsen C, Brøsen K, Jensen TS. The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. Clin Pharmacol Ther 1999; 66: 636-641.
44. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain. An update and effect related to mechanism of drug action. Pain 1999; 83: 389-400.
45. Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology 2000; 55; 915-920.
46. Arendt-Nielsen L, Pedersen P, Poulsen L, Andersen OK, Bjerring P, Coste I, Insuasty J, Sindrup SH, Drewes AM. A 5-HT antagonist (UP 26-91) versus codeine and placebo in a human experimental pain study. Pain Res Manage 2000; 14: 135-140.
47. Enggaard TP, Poulsen L, Arendt-Nielsen L, Gram LF, Sindrup SH. A placebo-controlled study of paroxetine and imipramine in human experimental pain models. Analgesia 2000; 5: 53-60.
48. Gaist D, Rodriguez LAG, Huertas C, Hallas J, Sindrup SH. Risk of myopathy and lipid lowering drugs: a population-based study. Epidemiology 2001; 12: 565-569.
49. Gaist D, Rodriguez LAG, Huertas C, Hallas J, Sindrup SH. Are users of lipid lowering drugs at increased risk of peripheral neuropathy. Eur J Clin Pharmacol 2001; 56: 931-933 .
50. Sindrup SH, Madsen C, Bach FW, Gram LF, Jensen TS. St. John’s wort has no effect in painful polyneuropathy. Pain 2001; 91: 361-365.
51. Enggaard TP, Poulsen L, Arendt-Nielsen L, Hansen SH, Bjørnsdottir I, Gram LF, Sindrup SH. The analgesic effect of codeine as compared to imipramine in different human experimental pain models. Pain 2001; 92: 271-282.
52. Enggaard TP, Poulsen L, Arendt-Nielsen L, Klitgaard NA, Gram LF, Sindrup SH. Specific effect of venlafaxine on single and repetitive experimental painful stimuli in humans. Clin Pharmacol Ther 2001; 69: 245-251.
53. Finnerup NB, Johannesen IL, Sindrup SH, Bach FW, Jensen TS. Pain and dysesthesia in patients with spinal cord injury: a postal survey. Spinal Cord 2001; 39: 256-262.
54. Sindrup SH, Gaist D, Johannsen L, Havsager AM, Homburg AM, Kjeldsen MJ, Madsen C, Dalsgaard NJ, Ellemann K, Smith T. Diagnostic yield by testing small fiber function in patients investigated for polyneurpathy. J Peripheral Nervous System 2001; 6: 214-218.
55. Johannsen L, Smith T, Havsager AM, Madsen C, Kjeldsen MJ, Dalsgaard NJ, Gaist D, Schrøder HD, Sindrup SH. Evaluation of patients with symptoms suggestive of chronic peripheral neuropathy. J Clin Neuromusc Disease 2001; 3: 47-52.
56. Jensen TS, Gottrup H, Sindrup SH, Bach FW. The clinical picture of neuropathic pain (Invited Review). Eur J Pharmacology 2001; 429: 1-11.
57. Sindrup SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia (Invited Review). Clin J Pain 2002; 18: 22-27.
58. Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS. Lamotrigine in spinal cord injury pain: a randomised controlled clinical trial. Pain 2002; 96: 375-383.
59. Bak S, Gaist D, Sindrup SH, Skytthe A, Christensen K.Genetic liability in stroke: a longterm follow-up study of Danish twins. Stroke 2002; 33: 769-774.
60. Gaist D, Jeppesen U, Andersen M, Rodriguez LAG, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology 2002; 58: 1333-1337.
61. Bak S, Sindrup SH, Alslev T, Kristensen O, Christensen K, Gaist D. Cessation of smoking after first-ever stroke. A follow-up study. Stroke 2002; 33: 2263-2269.
62. Sindrup SH, Bach FW, Madsen C, Gram LF. Jensen TS. Venlafaxine vs imipramine in painful polyneuropathy. A randomised controlled trial. Neurology 2003: 60:1284-1289.
63. Otto M, Bak S, Bach FW, Jensen TS, Sindrup SH. Pain phenomena and mechanisms in patients with painful polyneuropathy. Pain 2003; 101: 187-192.
64. Otto M , Bach FW, Jensen TS, Sindrup SH. Valproic acid has no effect on pain in polyneuropathy: a randomised, controlled trial. Neurology 2004; 62: 285-288.
65. Rasmussen PV, Sindrup SH, Jensen TS, Bach FW. Symptoms and signs in patients with suspected neuropathic pain. Pain 2004; 110:461-469.
66. Rasmussen PV, Sindrup SH, Jensen TS, Bach FW. TDM-based imipramine treatment in neuropathic pain. Ther Drug Monit 2004; 26: 352-360.
67. Rasmussen PV, Sindrup SH, Jensen TS, Bach FW. Therapeutic outcome in neuropathic pain: relationship to evidence of nervous system lesion. Eur J Neurol 2004; 11: 545-553.
68. Finnerup NB, Sindrup SH, Jensen TS. Anticonvulsant analgesics in peripheral and central neuropathic pain. Int J Pain Med Pall Care 2004; 3: 42-52.
69. Otto M , Bach FW, Jensen TS, Sindrup SH. Valproic acid has no effect on pain in polyneuropathy: a randomised, controlled trial. Neurology 2004;62:285-288.
70. Rasmussen PV, Sindrup SH, Jensen TS, Bach FW. Symptoms and signs in patients with suspected neuropathic pain. Pain 2004;110:461-469.
71. Rasmussen PV, Sindrup SH, Jensen TS, Bach FW. TDM-based imipramine treatment in neuropathic pain. Ther Drug Monit 2004;26:352-360.
72. Rasmussen PV, Sindrup SH, Jensen TS, Bach FW. Therapeutic outcome in neuropathic pain: relationship to evidence of nervous system lesion. Eur J Neurol 2004;11:545-553.
73. Finnerup NB, Sindrup SH, Jensen TS. Anticonvulsant analgesics in peripheral and central neuropathic pain. Int J Pain Med Pall Care 2004;3:42-52.
74. Gaist D, Pedersen L, Madsen C, Tsiropoulos I, Bak S, Sindrup SH, McGue M, Rasmussen BK, Christensen K. Longterm effects of migraine on cognitive function: a Danish population-based twin study. Neurology 2005;64:600-607.
75. Laugesen S, Enggaard TP, Pederesen RS, Sindrup SH, Brøsen K. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the analgesic effect of tramadol. Clin Phar Ther 2005;77:312-323.
76. Finnerup NB, Biering-Sørensen F, Johannesen IL, Terkelsen AJ, Juhl GI, Kristensen AD, Sindrup SH, Bach FW, Jensen TS. Intravenous lidocaine relieves spinal cord injury pain. Anesthesiology 2005;102:1023-1030.
77. Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005;96:399-409.
78. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289-305.
79. Enggaard TP, Klitgaard NA, Sindrup SH. Specific effect of levetiracetam in experimental human pain models. Eur J Pain 2006;10:193-198.
80. Enggaard TP, Poulsen L, Arendt-Nielsen L, Brøsen K, Ossig J, Sindrup SH. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg 2006;102:146-150.
81. Sindrup SH, Graf A, Sfikas N. The NK1-receptor antagonist TKA731 in painful diabetic polyneuropathy: a randomized, controlled trial. Eur J Pain 2006;10:567-571.
82. Søndergaard J, Foged A, Kragstrup J, Gaist D, Gram LF, Sindrup SH, Schaffalizky de Muckadell HU, Larsen BO, Herborg H, Andersen M. Intensive community pharmacy intervention had little impact on triptan consumption: a randomized controlled trial. Scand J Prim Health Care 2006;24:16-21.
83. Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, Sampaio C, Sindrup SH, Wiffen P. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006; 13: 153-169
84. Otto M, Bach FW, Jensen TS, Sindrup SH. Health-related quality of life and its predictive role for analgesic effect in patients with painful polyneuropathy. Eur J Pain 2007;11:572-578.
85. Otto M, Bach FW, Jensen TS, Brøsen K, Sindrup SH. Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial. Pain 2008;139:275-283.
86. Vilholm OJ, Cold S, Rasmussen L, Sindrup SH. The postmastectomy pain syndrome: an epidemiological study on the prevalence of chronic pain after surgery for breast cancer. Br J Cancer 2008;19;99:604-10
87. Vilholm OJ, Cold S, Rasmussen L, Sindrup SH. Effect of levetiracetam on the postmastectomy pain syndrome. Eur J Neurol 2008;15:851-7
88. Vilholm OJ, Cold S, Rasmussen L, Sindrup SH. Sensory function and pain in a population of patients treated for breast cancer. Acta Anaesthesiol Scand 2009;53:800-6
89. Finnerup NB, Grydehøj J, Bing J, Johannesen IL, Biering-Sørensen F, Sindrup SH, Jensen TS. Levetiracetam in spinal cord injury pain: a randomized controlled trial. Spinal Cord 2009;47:861-
90. Noehr-Jensen L, Zwisler ST, Larsen F, Sindrup SH, Damkier P, Brosen K. Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. Clin Pharmacol Ther 2009;86:626-33.
91. Noehr-Jensen L, Zwisler ST, Larsen F, Sindrup SH, Damkier P, Nielsen F, Brosen K.Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. Eur J Clin Pharmacol 2009;65:887-94
92. Zwisler ST, Enggaard TP, Noehr-Jensen L, Pedersen RS, Mikkelsen S, Nielsen F, Brosen K, Sindrup SH. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin Pharmacol Toxicol 2009;104:335-44
93. Harbo T, Andersen H, Hess A, Hansen K, Sindrup SH, Jakobsen J. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol 2009;16:631-8
94. Zwisler ST, Enggaard TP, Mikkelsen S, Brosen K, Sindrup SH. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. Acta Anaesthesiol Scand 2010;54:232-40
95. Zwisler ST, Enggaard TP, Noehr-Jensen L, Mikkelsen S, Verstuyft C, Becquemont L, Sindrup SH, Brosen K. The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundam Clin Pharmacol 2010;24:517-24
96. Leo CA, Sindrup SH, Gaist D. Unchanged incidence of Guillain-Barré syndrome in the Funen county during a decade. Ugeskr Laeger 2010;172:3093-7
97. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150:573-581
98. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33:2285-93
99. Brasch-Andersen C, Møller MU, Christiansen L, Thinggaard M, Otto M, Brøsen K, Sindrup SH. A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C). Eur J Clin Pharmacol 2011;67:1131-7
100. Holbech JV, Otto M, Bach FW, Jensen TS, Sindrup SH. The anticonvulsant levetiracetam for the treatment of pain in polyneuropathy: a randomized, placebo-controlled, cross-over trial. Eur J Pain 2011;15:608-14
101. Tesfaye S, Vileikyte L, Rayman G, Sindrup S, Perkins B, Baconja M, Vinik A, Boulton A; on behalf of the Toronto Expert Panel on Diabetic Neuropathy*. Painful Diabetic Peripheral Neuropathy: Consensus Recommendations on Diagnosis, Assessment and Management.Diabetes Metab Res Rev 2011;27:629-38
102. Zwisler ST, Enggaard TP, Mikkelsen S, Verstuyft C, Becquemont L, Sindrup SH, Brosen K. Lack of Association of OPRM1 and ABCB1 Single-Nucleotide Polymorphisms to Oxycodone Response in Postoperative Pain. J Clin Pharmacol 2012;52:234-242
103. Falah M, Madsen C, Holbech JV, Sindrup SH. A randomized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis. Eur J Pain 2012;16:860-9
104. Sindrup SH, Konder R, Lehmann R, Meier T, Winkel M, Ashworth J, Baron R, Jensen TS.Randomized controlled trial of the combined monoaminergic and opioid investigational compound GRT9906 in painful polyneuropathy. Eur J Pain 2012;16:849-59
105. Moth Henriksen M, Kolmos EB, Abildgaard N, Schrøder HD, Sindrup S. Polyneuropathy associated with monoclonal gammopathy of undetermined significance. Ugeskr Laeger 2012;174:2630-4
106. Markvardsen LH, Debost JC, Harbo T, Sindrup SH, Andersen H, Christiansen I, Otto M, Olsen NK, Lassen LL, Jakobsen J; Danish CIDP and MMN Study Group. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2013;20:836-42
107. Krøigård T, Schrøder HD, Qvortrup C, Eckhoff L, Pfeiffer P, Gaist D, Sindrup SH. Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies. Eur J Neurol. 2014;21:623-629.
108. Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, Jensen TS, Sindrup SH. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype. A randomized, double-blind, placebo-controlled and phenotype-stratified study. Pain 2014; doi: 10.1016/j.pain.2014.08.014. [Epub ahead of print]
109. Krøigård T, Gaist D, Otto M, Højlund D, Selmar P, Sindrup SH. Spontaneous and temporal changes and variability of peripheral nerve conduction analyzed using a random effects model. J Clin Neurophysiol 2014 31: 387-391.


Editorials and letters
1. Gaist D, Sindrup SH, Hallas J, Gram LF. Misuse of sumatriptan (research letter). Lancet 1994; ii: 1090.
2. Sindrup SH, Brøsen K. Kombinationspræparater af codein og paracetamol. Ugeskr. Læger 1998; 160: 448-449.
3. Jensen TS, Bach FW, Sindrup SH. Kroniske neuropatiske smerter efter kirurgi. Ugeskr. Læger 1999; 161: 3680-3681.
4. Jensen TS, Sindrup SH, Bach FW. Test the classification of pain. Pain 2002; 96: 407-408.
5. Jensen TS, Sindrup SH. Opioids: a way to control central pain ? Neurology 2002; 58: 517-518.
6. Sindrup SH, Otto M, Bach FW, Jensen TS. Sodium valproate in painful diabetic polyneuropathy. Acta Neurol Scand 2003; 108: 443-444
7. Sindrup SH, Jensen TS. Are sodium channel blockers useless in peripheral neuropathic pain ? Pain 2007;128:6-7.
8. Sindrup SH. Nicotinic acetylcholine receptor agonism: progress in the management of neuropathic pain? Pain 2009;146:227-8.
9. Sindrup SH, Finnerup NB, Jensen TS. Tailored treatment of peripheral neuropathic pain. Pain 2012;153:1781-2
10. Sindrup SH. The obligation to publishing negative outcome data from neuropathic pain clinical trials. Scand J Pain 2013:4:75-76

Kapitler til hånd- og lærebøger mm
1. Sindrup SH. Antidepressants as analgesics. In: Yaksh TL, Lynch C, Zapol WM, Maze M, Biebuyck JF, Saidman LJ (eds.): Anesthesia. Biologic foundations. Lippen¬cott-Raven Publishers, Philadelphia 1997, pp. 987-997.
2. Sindrup SH. Antidepressants and chronic pain. In: Wilson P, Haddox D, Jensen TS (eds). Clinical pain management. Chronic pain. Arnold, London 2003, pp 239-249.
3. Sindrup SH, Bach FW. Antidepressants, antiepileptics and antiarrhytmics. In: Wilson P, Haddox D, Jensen TS (eds). Clinical pain management. Treatment. Arnold, London 2003, pp 101-109.
4. Sindrup SH, Finnerup NB, Otto M, Jensen TS. Principles of pharmacological treatment. In: Cervero F, Jensen TS (eds.). Handbook of Clinical Neurology, Vol. 81. Pain. Elsevier, Amsterdam 2006, 843-853.
5. Sindrup SH, Jensen TS. Antidepressant in neuropathic pain. In: Schmidt RF, Willis WD (eds.). Encyclopedia of pain. Springer, Berlin/Heidelberg 2007.
6. Finnerup NB, Sindrup SH. Central pain, pharmacological treatments. In: Schmidt RF, Willis WD (eds.). Encyclopedia of pain. Springer, Berlin/Heidelberg 2007
7. Sindrup SH, Jensen TS. Smertefysiologi. In: Brøsen K, Simonsen U, Kampmann JP, Thirstrup S. Basal og klinisk farmakologi. FADL’s Forlag 2014, 201-7
8. Sindrup SH. Analgetika. In: Brøsen K, Simonsen U, Kampmann JP, Thirstrup S. Basal og klinisk farmakologi. FADL’s Forlag 2014, 502-16
9. Finnerup NB, Sindrup SH, Jensen TS. Management of painful neuropathies. In: Said G, Krarup C. Handbook of Clinical Neurology, Vol 115 (3rd series). Elsevier 2013, 279-290.

Ti væsentlige artikler: 18, 23, 41, 45, 60, 62, 77, 97, 107, 108.